David G.
Maloney
M.D.
Ph.D.
Education and Training
- M.D., Stanford University
- Ph.D., Stanford University
- Residency, Brigham and Women’s Hospital
- Fellowship, Stanford University
Research and/or clinical interests
Dr. David Maloney's primary clinical focus was developing and testing new immunotherapies for the treatment of cancer. He has been an expert on blood-forming (hematopoietic) stem cell transplantation (HCT), using a matched donor’s (allogeneic) or a patient’s own (autologous) stem cells in treatments for patients with hematologic malignancies. Recognizing that standard pre-transplant regimens are too toxic for many patients, Dr. Maloney and Fred Hutch colleagues developed a less toxic, “reduced intensity” (nonmyeloablative) regimen that can more safely provide long-term remissions for patients with chronic lymphocytic leukemia, non-Hodgkin lymphoma and myeloma after allogeneic HCT.
More recently, his focus was on using genetically engineered T cells (such as CAR-T) to treat patients with leukemia, lymphoma, myeloma and selected other cancers. With colleagues at Fred Hutch and UW, the Bezos Family Immunotherapy Clinic at Fred Hutch was established, dedicated to the delivery of these novel cellular immunotherapy products. As the first Medical Director of this program, Dr. Maloney provided oversight and guidance for the cellular immunotherapy program at Fred Hutch.